These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 27168098)

  • 1. Assessment of pharmacogenetic tests: presenting measures of clinical validity and potential population impact in association studies.
    Tonk ECM; Gurwitz D; Maitland-van der Zee AH; Janssens ACJW
    Pharmacogenomics J; 2017 Jul; 17(4):386-392. PubMed ID: 27168098
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacogenetics of drug hypersensitivity.
    Phillips EJ; Mallal SA
    Pharmacogenomics; 2010 Jul; 11(7):973-87. PubMed ID: 20602616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. HLA-B*5701 screening for susceptibility to abacavir hypersensitivity.
    Lucas A; Nolan D; Mallal S
    J Antimicrob Chemother; 2007 Apr; 59(4):591-3. PubMed ID: 17317695
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Prospective validation of a pharmacogenetic test: the PREDICT-1 study].
    Muñoz de Benito RM; Arribas López JR
    Enferm Infecc Microbiol Clin; 2008 May; 26 Suppl 6():40-4. PubMed ID: 18680695
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics: The right drug for you.
    Drew L
    Nature; 2016 Sep; 537(7619):S60-2. PubMed ID: 27602742
    [No Abstract]   [Full Text] [Related]  

  • 7. HLA-B*5701 screening prior to abacavir prescription: clinical and laboratory aspects.
    Nolan D
    Crit Rev Clin Lab Sci; 2009; 46(3):153-65. PubMed ID: 19514905
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The contribution of pharmacogenetics to pharmacovigilance.
    Bondon-Guitton E; Despas F; Becquemont L
    Therapie; 2016 Apr; 71(2):223-8. PubMed ID: 27080842
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacogenomics testing for type B adverse drug reactions to anti-infective drugs: the example of hypersensitivity to abacavir.
    Agundez JA; Esguevillas G; Amo G; Garcia-Martin E
    Recent Pat Antiinfect Drug Discov; 2014; 9(2):151. PubMed ID: 25891395
    [No Abstract]   [Full Text] [Related]  

  • 10. Genetic screening to prevent abacavir hypersensitivity reaction: are we there yet?
    Phillips EJ
    Clin Infect Dis; 2006 Jul; 43(1):103-5. PubMed ID: 16758425
    [No Abstract]   [Full Text] [Related]  

  • 11. Studies on abacavir-induced hypersensitivity reaction: a successful example of translation of pharmacogenetics to personalized medicine.
    Guo Y; Shi L; Hong H; Su Z; Fuscoe J; Ning B
    Sci China Life Sci; 2013 Feb; 56(2):119-24. PubMed ID: 23393027
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic association studies to detect adverse drug reactions: abacavir hypersensitivity as an example.
    Hughes AR; Brothers CH; Mosteller M; Spreen WR; Burns DK
    Pharmacogenomics; 2009 Feb; 10(2):225-33. PubMed ID: 19207023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01.
    Sousa-Pinto B; Pinto-Ramos J; Correia C; Gonçalves-Costa G; Gomes L; Gil-Mata S; Araújo L; Delgado L
    J Allergy Clin Immunol; 2015 Oct; 136(4):1092-4.e3. PubMed ID: 25934581
    [No Abstract]   [Full Text] [Related]  

  • 14. Genome-wide approaches to identify pharmacogenetic contributions to adverse drug reactions.
    Nelson MR; Bacanu SA; Mosteller M; Li L; Bowman CE; Roses AD; Lai EH; Ehm MG
    Pharmacogenomics J; 2009 Feb; 9(1):23-33. PubMed ID: 18301416
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The cost-effectiveness of HLA-B*5701 genetic screening to guide initial antiretroviral therapy for HIV.
    Schackman BR; Scott CA; Walensky RP; Losina E; Freedberg KA; Sax PE
    AIDS; 2008 Oct; 22(15):2025-33. PubMed ID: 18784465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct PCR: a new pharmacogenetic approach for the inexpensive testing of HLA-B*57:01.
    Cascella R; Strafella C; Ragazzo M; Zampatti S; Borgiani P; Gambardella S; Pirazzoli A; Novelli G; Giardina E
    Pharmacogenomics J; 2015 Apr; 15(2):196-200. PubMed ID: 25201286
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Abacavir pharmacogenetics--from initial reports to standard of care.
    Martin MA; Kroetz DL
    Pharmacotherapy; 2013 Jul; 33(7):765-75. PubMed ID: 23649914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic accuracy of HLA-B*57:01 screening for the prediction of abacavir hypersensitivity and clinical utility of the test: a meta-analytic review.
    Cargnin S; Jommi C; Canonico PL; Genazzani AA; Terrazzino S
    Pharmacogenomics; 2014 May; 15(7):963-76. PubMed ID: 24956250
    [TBL] [Abstract][Full Text] [Related]  

  • 19. PREDICT-1 (CNA106030): the first powered, prospective trial of pharmacogenetic screening to reduce drug adverse events.
    Hughes S; Hughes A; Brothers C; Spreen W; Thorborn D;
    Pharm Stat; 2008; 7(2):121-9. PubMed ID: 17534855
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HLA-associated drug hypersensitivity and the prediction of adverse drug reactions.
    Negrini S; Becquemont L
    Pharmacogenomics; 2017 Oct; 18(15):1441-1457. PubMed ID: 29017379
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.